Product Images Lenalidomide

Each capsule contains Lenalidomide 5 mg and should be used according to the prescribing information for dosage and administration. The medicine should be kept out of the reach of children and stored at a temperature of 20° to 25°C. The medication is manufactured by Mylan Pharmaceuticals Inc in India and should be stored in a tight, light-resistant container with child-resistant closure. The medicine can cause human birth defects so a pharmacist should dispense it along with a Medication Guide for each patient. Variable data coding such as LOT and EXP should also be printed wherever applicable. NDC 0378-1936-28 is the product code for Lenalidomide Capsules with 28 capsules in each pack.*

Each capsule contains 10mg of Lenalidomide. This medicine comes with prescription information for dosing and administration. It is important to keep the capsules out of reach of children and to store them at a temperature between 20°C and 25°C. The medication may cause potential birth defects. The medicine is manufactured by Mylan Pharmaceuticals in India and comes in a bottle of 28 capsules. The NDC code for the product is 0378-1937-28. The medicine should be dispensed in a tight and light-resistant container with a child-resistant closure. The LOT and EXP information should be printed with the variable data coding.*

This is a medication in capsule form containing Lenalidomide and is typically taken as prescribed by a doctor. The medication should be kept out of reach of children in a closed container at room temperature as directed by the USP. The medication is manufactured by Mylan Pharmaceuticals and is made in India. The National Drug Code for this medication is 0378-1941-21. The medication should be dispensed in a light-resistant container that is child-resistant. The accompanying medication guide should be given to each patient. The Lot and Exp of the medication will be printed along with variable data online coding where applicable.*

This appears to be the chemical name or formula for a compound: 3-(4-Amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl) piperidine-2,6-dione, commonly known as NH. It is not possible to provide any further useful information without additional context about the compound or its purpose.*

This appears to be a table or chart showing data related to survival probability, progression-free survival, and number of subjects in a study involving treatments of dexamethasone, melphalan, prednisone, thalidomide, and lenalidomide capsules. The table includes percentages, confidence intervals, hazard ratios, and other statistical information, but a specific interpretation or conclusion cannot be made without additional context.*

This is a statistical analysis of a clinical trial comparing the treatment with Lenalidomide and Dex (254 participants) to placebo and Dex (50 participants) for Time to Progression in months. The results show a significant difference between the two treatments with a HR (Hazard Ratio) of 0.285 (95% confidence interval: 0.210-0.386) and a p-value < 0.001.*

The text represents a graph or a chart displaying the proportion of subjects and the time to progression in months. It includes data on HR (95% Cl) and Log Rank p values for two treatments: Lenalidomide/Dex and Placebo/Dex. The chart shows that the Lenalidomide/Dex treatment had a significantly higher proportion of subjects with a lower time to progression compared to the placebo/Dex treatment.*

The text describes survival probability and compares the efficacy of Lenalidomide versus placebo in terms of HR, median survival, and progression-free survival. It also shows the number of subjects who experienced PFS events with each treatment.*